These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

197 related articles for article (PubMed ID: 35614482)

  • 1. Efficacy and safety of artesunate for patients with IgA nephropathy: a study protocol for a multicenter, double-blind, randomized, placebo-controlled trial.
    Chen Q; Wang Z; Lv J; Liu L; Li H; Sun W; Huo Y; Guo Y; Shen C; Li S; Chen Z; Zhou J
    Trials; 2022 May; 23(1):444. PubMed ID: 35614482
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Treatment effects of Chinese medicine (Yi-Qi-Qing-Jie herbal compound) combined with immunosuppression therapies in IgA nephropathy patients with high-risk of end-stage renal disease (TCM-WINE): study protocol for a randomized controlled trial.
    Li S; Li JP
    Trials; 2020 Jan; 21(1):31. PubMed ID: 31907076
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effects of Hydroxychloroquine on Proteinuria in IgA Nephropathy: A Randomized Controlled Trial.
    Liu LJ; Yang YZ; Shi SF; Bao YF; Yang C; Zhu SN; Sui GL; Chen YQ; Lv JC; Zhang H
    Am J Kidney Dis; 2019 Jul; 74(1):15-22. PubMed ID: 30922594
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Abelmoschus manihot - a traditional Chinese medicine versus losartan potassium for treating IgA nephropathy: study protocol for a randomized controlled trial.
    Li P; Chen YZ; Lin HL; Ni ZH; Zhan YL; Wang R; Yang HT; Fang JA; Wang NS; Li WG; Sun XF; Chen XM
    Trials; 2017 Apr; 18(1):170. PubMed ID: 28395659
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A phase 2b, randomized, double-blind, placebo-controlled, clinical trial of atacicept for treatment of IgA nephropathy.
    Lafayette R; Barbour S; Israni R; Wei X; Eren N; Floege J; Jha V; Kim SG; Maes B; Phoon RKS; Singh H; Tesař V; Lin CJF; Barratt J
    Kidney Int; 2024 Jun; 105(6):1306-1315. PubMed ID: 38552841
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Targeted-release budesonide versus placebo in patients with IgA nephropathy (NEFIGAN): a double-blind, randomised, placebo-controlled phase 2b trial.
    Fellström BC; Barratt J; Cook H; Coppo R; Feehally J; de Fijter JW; Floege J; Hetzel G; Jardine AG; Locatelli F; Maes BD; Mercer A; Ortiz F; Praga M; Sørensen SS; Tesar V; Del Vecchio L;
    Lancet; 2017 May; 389(10084):2117-2127. PubMed ID: 28363480
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Lisinopril versus lisinopril and losartan for mild childhood IgA nephropathy: a randomized controlled trial (JSKDC01 study).
    Shima Y; Nakanishi K; Sako M; Saito-Oba M; Hamasaki Y; Hataya H; Honda M; Kamei K; Ishikura K; Ito S; Kaito H; Tanaka R; Nozu K; Nakamura H; Ohashi Y; Iijima K; Yoshikawa N;
    Pediatr Nephrol; 2019 May; 34(5):837-846. PubMed ID: 30284023
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Hong Kong study using valsartan in IgA nephropathy (HKVIN): a double-blind, randomized, placebo-controlled study.
    Li PK; Leung CB; Chow KM; Cheng YL; Fung SK; Mak SK; Tang AW; Wong TY; Yung CY; Yung JC; Yu AW; Szeto CC;
    Am J Kidney Dis; 2006 May; 47(5):751-60. PubMed ID: 16632013
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Phase 2 Trial of Cemdisiran in Adult Patients with IgA Nephropathy: A Randomized Controlled Trial.
    Barratt J; Liew A; Yeo SC; Fernström A; Barbour SJ; Sperati CJ; Villanueva R; Wu MJ; Wang D; Borodovsky A; Badri P; Yureneva E; Bhan I; Cattran D;
    Clin J Am Soc Nephrol; 2024 Apr; 19(4):452-462. PubMed ID: 38214599
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effect of Oral Methylprednisolone on Clinical Outcomes in Patients With IgA Nephropathy: The TESTING Randomized Clinical Trial.
    Lv J; Zhang H; Wong MG; Jardine MJ; Hladunewich M; Jha V; Monaghan H; Zhao M; Barbour S; Reich H; Cattran D; Glassock R; Levin A; Wheeler D; Woodward M; Billot L; Chan TM; Liu ZH; Johnson DW; Cass A; Feehally J; Floege J; Remuzzi G; Wu Y; Agarwal R; Wang HY; Perkovic V;
    JAMA; 2017 Aug; 318(5):432-442. PubMed ID: 28763548
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A Randomized, Controlled Trial of Rituximab in IgA Nephropathy with Proteinuria and Renal Dysfunction.
    Lafayette RA; Canetta PA; Rovin BH; Appel GB; Novak J; Nath KA; Sethi S; Tumlin JA; Mehta K; Hogan M; Erickson S; Julian BA; Leung N; Enders FT; Brown R; Knoppova B; Hall S; Fervenza FC
    J Am Soc Nephrol; 2017 Apr; 28(4):1306-1313. PubMed ID: 27821627
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Randomized controlled trial of mycophenolate mofetil in children, adolescents, and adults with IgA nephropathy.
    Hogg RJ; Bay RC; Jennette JC; Sibley R; Kumar S; Fervenza FC; Appel G; Cattran D; Fischer D; Hurley RM; Cerda J; Carter B; Jung B; Hernandez G; Gipson D; Wyatt RJ
    Am J Kidney Dis; 2015 Nov; 66(5):783-91. PubMed ID: 26209543
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Tacrolimus decreases albuminuria in patients with IgA nephropathy and normal blood pressure: a double-blind randomized controlled trial of efficacy of tacrolimus on IgA nephropathy.
    Kim YC; Chin HJ; Koo HS; Kim S
    PLoS One; 2013; 8(8):e71545. PubMed ID: 23977072
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The Therapeutic Evaluation of Steroids in IgA Nephropathy Global (TESTING) Study: Trial Design and Baseline Characteristics.
    Wong MG; Lv J; Hladunewich MA; Jha V; Hooi LS; Monaghan H; Zhao M; Barbour S; Reich HN; Cattran D; Glassock R; Levin A; Jardine MJ; Wheeler DC; Woodward M; Billot L; Chan TM; Liu ZH; Johnson DW; Cass A; Feehally J; Floege J; Remuzzi G; Wu Y; Agarwal R; Zhang H; Perkovic V;
    Am J Nephrol; 2021; 52(10-11):827-836. PubMed ID: 34731857
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The long-term outcome of patients with IgA nephropathy treated with fish oil in a controlled trial. Mayo Nephrology Collaborative Group.
    Donadio JV; Grande JP; Bergstralh EJ; Dart RA; Larson TS; Spencer DC
    J Am Soc Nephrol; 1999 Aug; 10(8):1772-7. PubMed ID: 10446945
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A Phase 2 Trial of Sibeprenlimab in Patients with IgA Nephropathy.
    Mathur M; Barratt J; Chacko B; Chan TM; Kooienga L; Oh KH; Sahay M; Suzuki Y; Wong MG; Yarbrough J; Xia J; Pereira BJG;
    N Engl J Med; 2024 Jan; 390(1):20-31. PubMed ID: 37916620
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The effects of dual blockade of the renin-angiotensin system on urinary protein and transforming growth factor-beta excretion in 2 groups of patients with IgA and diabetic nephropathy.
    Song JH; Lee SW; Suh JH; Kim ES; Hong SB; Kim KA; Kim MJ
    Clin Nephrol; 2003 Nov; 60(5):318-26. PubMed ID: 14640237
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Efficacy and safety of angiotensin-converting enzyme inhibitors or angiotensin receptor blockers for IgA nephropathy in children.
    Vaz de Castro PAS; Bitencourt L; Pereira BWS; Lima AQR; Hermida HS; Moreira Neto CR; Mestriner MD; Simões E Silva AC
    Pediatr Nephrol; 2022 Mar; 37(3):499-508. PubMed ID: 34686915
    [TBL] [Abstract][Full Text] [Related]  

  • 19. IgACE: a placebo-controlled, randomized trial of angiotensin-converting enzyme inhibitors in children and young people with IgA nephropathy and moderate proteinuria.
    Coppo R; Peruzzi L; Amore A; Piccoli A; Cochat P; Stone R; Kirschstein M; Linné T
    J Am Soc Nephrol; 2007 Jun; 18(6):1880-8. PubMed ID: 17513327
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Experimental evidence of pathogenic role of IgG autoantibodies in IgA nephropathy.
    Moldoveanu Z; Suzuki H; Reily C; Satake K; Novak L; Xu N; Huang ZQ; Knoppova B; Khan A; Hall S; Yanagawa H; Brown R; Winstead CJ; O'Quinn DB; Weinmann A; Gharavi AG; Kiryluk K; Julian BA; Weaver CT; Suzuki Y; Novak J
    J Autoimmun; 2021 Mar; 118():102593. PubMed ID: 33508637
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.